Published in Hepatitis Weekly, September 27th, 2004
The private placement is part of a licensing agreement between Transition and Novo Nordisk. The shares issued to Novo Nordisk are subject to a 4-month hold period.
Proceeds from the financing will be used by Transition for ongoing research and development and for general corporate purposes.
Transition is a product-focused biopharmaceutical company, developing novel approaches and therapeutics for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly